Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Soleno Therapeutics, Inc. (NASDAQ:SLNO) has a consensus Buy rating, as all 13 analysts covering the stock have assigned a ‘Buy’ or equivalent rating. With a median price of $110, the stock boasts an upside potential of around 114%.

On November 5, Kristen Kluska, an analyst at Cantor Fitzgerald, reiterated a ‘Buy’ rating on Soleno Therapeutics, Inc. (SLNO), with a price target of $123. Similarly, Kate Dellorusso from LifeSci Capital also maintained the ‘Buy’ rating and a $110 price target.

Cherries/Shutterstock.com

On the same day, Wells Fargo analyst Derek Archila reduced his price target on the stock to $106 from $123, while keeping an ‘Overweight’ rating. The analyst believes Vykat XR will be a “$1B-plus drug in Prader-Willi syndrome.”

Later on November 17, Wolfe Research began coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) with an ‘Outperform’ rating and a $75 price target, suggesting an upside potential of nearly 44% from the current price. This optimism surrounds the company’s recent FDA approval of Vykat XR, which the analyst regards as “the only approved therapy for hyperphagia in PWS.” With the approval of its Prader-Willi syndrome solution, Soleno Therapeutics, Inc. (NASDAQ:SLNO) is “entering a new phase of value creation,” the research firm stated.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a California-based clinical-stage biopharmaceutical company specializing in novel therapeutics to treat serious illnesses. Founded in 1999, the company provides Diazoxide Choline Extended-Release tablets.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.